Hours after President Trump said Sunday he had "second thoughts" about escalating the trade war with China, the White House sought to explain his remark because it was...Politicsread more
Clouding the G-7 gathering, which represents the world's major industrial economies, are the tit-for-tat tariffs between Washington and Beijing.Politicsread more
President Donald Trump said that he would have a major trade deal with U.K. after it leaves the European Union.Politicsread more
Despite Kudlow's expectations, China said on Saturday that it strongly opposes Trump's decision to levy additional tariffs on $550 billion worth of Chinese goods, and warned...Politicsread more
President Donald Trump said Sunday he was not happy after North Korea launched short-range ballistic missiles over the weekend.Politicsread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
The announcement for Target also comes on the heels of a strong quarterly earnings report, where it showed it drove more people to stores and got them to spend more money...Retailread more
The Goldman Sachs technology M&A team, led by Sam Britton, has cashed in on its software focus and decades of experience to dominate 2019's biggest deals.Technologyread more
American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
The summit comes amid fears over a global economic slowdown, and U.S. tensions over trade allies, Iran and Russia.Politicsread more
OxyContin-maker Purdue Pharma is exploring bankruptcy protection amid accusations of igniting a nationwide opioid crisis by ruthlessly marketing and misleading doctors and patients about the dangers of the highly addictive narcotic.
Purdue, founded in the 1950s by brothers Arthur, Mortimer and Raymond Sackler, is looking at filing for Chapter 11 bankruptcy to protect its assets against thousands of lawsuits for its role in the opioid epidemic, according to a Reuters report.
A bankruptcy filing is not certain, Reuters reported, citing anonymous sources. Purdue Pharma has not made any final decisions and could instead continue fighting the lawsuits, Reuters said.
"As a privately-held company, it has been Purdue Pharma's longstanding policy not to comment on our financial or legal strategy," Purdue said in a statement. "We are, however, committed to ensuring that our business remains strong and sustainable. We have ample liquidity and remain committed to meeting our obligations to the patients who benefit from our medicines, our suppliers and other business partners."
Purdue and other manufacturers face a trial in May in a case brought by Oklahoma Attorney General Mike Hunter. Accusations against the Stamford, Connecticut-based company include downplaying the addiction risk while overstating the benefits of opioids.
They've also been accused of urging sales representatives to advise doctors to prescribe the highest dosage of the painkiller because it was more profitable.
The company has denied any wrongdoing. They say labels for its painkiller carried warnings about the risk of abuse and misuse associated with the drugs.
OxyContin is a prescription drug used to treat moderate to severe pain in adults. From 1999 to 2017, nearly 218,000 people have died in the United States from overdoses related to prescription opioids, according to the U.S. Centers for Disease Control and Prevention. OxyContin first came on the market in 1996.
In late 2017, Purdue launched an advertising campaign meant to show it is doing its part to stem the epidemic. The ads, which appeared in several national and public newspapers, emphasized that the company is a "research-driven, science-based" entity and dedicated to discovering safer new pain medications.